Article and Video CATEGORIES
Dr. Ravi Salgia from University of Chicago explains his approach to management of acquired resistance to a targeted therapy for advanced NSCLC, both in the setting of a single area of progression and also when disease progression is more diffuse.
[powerpress]
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Forum Discussions
Thank you for your comments Janine. Makes sense.
Hi survivour,
You have been through a lot already at such a young age, probably too much for someone online to say much. Perhaps your haemotologist and pulmonologist consult to...
Hello and welcome to Grace. I'm sorry you need to look for this info. Stage IV rectal cancer survival rate depends on whether cancer is contained regionally or has spread to...
Hi cancersurvivour and welcome to Grace. Congrats on the "previous" aspect of your blood cancer. A haematologist is just the person to keep an eye on you with CT scans. Your...